Pin On Press Releases
New Phase 3 data with aprocitentan for patients with resistant hypertension has been presented at the American Society of Nephrology Kidney Week 2023. IDIA today announced its financial results for the first quarter of 2023 Commercial highlights QUVIVIQ daridorexant total net sales of CHF 43 million in Q1 2023. 10 2022 PRNewswire -- The approval of QUVIVIQ 25 50 mg is based on a robust Phase 3 clinical program that demonstrated significant improvement versus. IDIA today announced that the US Food and Drug Administration FDA has approved QUVIVIQ daridorexant 25 mg and 50 mg for the treatment of adult patients. IDIA today announced that it has submitted a New Drug Application NDA to the US Food and Drug Administration FDA seeking approval for aprocitentan..
Idorsia the Switzerland-based biotechnology company disclosed Friday a broad cost-cutting initiative that could include as many as 500 layoffs. The company is laying off 300 people predominantly in RD and associated functions according to an announcement Tuesday About 175 other positions were made redundant by. Up to 500 roles at Idorsia are at risk as the Swiss biotech tries to halve its cash burn while it waits for its approved insomnia treatment Quviviq to pay off. Endpoints News noted that sales of Idorsias insomnia drug Quviviq have so far been disappointing According to the companys announcement its cash runway now extends into next year. The news comes after Idorsia announced potential layoffs and cost-reduction initiatives including the sale of its Asia Pacific operations in July due to lower than anticipated sales in..
Phase One Of Roche S Basel Hq Opens With Herzog De Meuron Designed Office Tower Office Tower Roche Architecture Magazines
Idorsia published its full year financial results 2022 on Tuesday February 7 2023 Investor webcast Investor presentation Read the media release Idorsia presents at the 41st JP. IDIA today announced its financial results for the first nine months of 2023 Business highlights Transaction with Sosei Heptares hereafter referred as the. IDIA today announced its financial results for the first half of 2023 Business highlights Transaction with Sosei Heptares Idorsia sells its Asia Pacific ex-China. IDIA today announced that it has entered into exclusive negotiations with an undisclosed party regarding its operating businesses in the Asia Pacific ex. 10 2022 PRNewswire -- Idorsia Pharmaceuticals US Inc Today announced that TRICARE the healthcare program for active and retired US..
New Phase 3 data with aprocitentan for patients with resistant hypertension has been presented at the American Society of Nephrology Kidney Week 2023. IDIA today announced its financial results for the first quarter of 2023 Commercial highlights QUVIVIQ daridorexant total net sales of CHF 43 million in Q1 2023. 10 2022 PRNewswire -- The approval of QUVIVIQ 25 50 mg is based on a robust Phase 3 clinical program that demonstrated significant improvement versus. IDIA today announced that the US Food and Drug Administration FDA has approved QUVIVIQ daridorexant 25 mg and 50 mg for the treatment of adult patients. IDIA today announced that it has submitted a New Drug Application NDA to the US Food and Drug Administration FDA seeking approval for aprocitentan..
Komentar